Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Novel Protease-Mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances Directionality of CAR-T Cell Activity and Improves Target Cell Specificity

Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori

Blood (2022) 140 (Supplement 1): 4533–4534.

https://doi.org/10.1182/blood-2022-165658

Published: 2022

Journal Articles

TPL2, a New Prognostic Factor and a Potential Therapeutic Target in ABC-DLBCL

Kota Yoshifuji, Yotaro Motomura, Makiko Saito, Ayako Nogami, Genji Kawade, Shiori Watabe, Kouhei Yamamoto, Takehiko Mori, Toshikage Nagao

Blood (2022) 140 (Supplement 1): 5915–5916.

https://doi.org/10.1182/blood-2022-162875

Published: 2022

Journal Articles

A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): "Double Arm" CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD, PhD, BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-140642

Published: 2020

Journal Articles

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Watanabe Daisuke, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Kouhei Yamamoto, Takeo Fujiwara, MD, Yoko Edahiro, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Tetsuya Fukuda, MD PhD, Ayako Arai, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata

Blood (2019) 134 (Supplement_1): 1690.

https://doi.org/10.1182/blood-2019-122652

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Ayako Nogami, MD PhD BPharm, Daisuke Watanabe, MD, Keigo Okada, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Toshikage Nagao, MD, PhD, Shuji Tohda, MD, PhD, Osamu Miura, MD, PhD

Blood (2019) 134 (Supplement_1): 1425.

https://doi.org/10.1182/blood-2019-123183

Published: 2019

Journal Articles

A Novel Cell Line, Tnet-2, Derived from "Triple-Negative" Essential Thrombocythemia

Satoru Aoyama, MD MMSc, Toshikage Nagao, MD PhD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, Shinya Ishida, MD, Ayako Nogami, MD, PhD, Yoshihiro Umezawa, MD, Ken Watanabe, MD PhD, Masahide Yamamoto, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata, MD

Blood (2018) 132 (Supplement 1): 5493.

https://doi.org/10.1182/blood-2018-99-114457

Published: 2018

Journal Articles

Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells

Hiroki Akiyama, MD, Yoshihiro Umezawa, MD, Keigo Okada, MD, Shinya Ishida, MD, Ayako Nogami, MD, PhD, Osamu Miura, MD, PhD

Blood (2017) 130 (Supplement 1): 2531.

https://doi.org/10.1182/blood.V130.Suppl_1.2531.2531

Published: 2017

Journal Articles

FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression

Ayako Nogami, MD PhD, Keigo Okada, MD, Gaku Oshikawa, MD PhD, Shinya Ishida, MD, Hiroki Akiyama, MD, Yoshihiro Umezawa, MD, Tetsuya Kurosu, MD PhD, Osamu Miura, MD PhD

Blood (2015) 126 (23): 1270.

https://doi.org/10.1182/blood.V126.23.1270.1270

Published: 2015

NARROW

Novel Protease-Mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances Directionality of CAR-T Cell Activity and Improves Target Cell Specificity

TPL2, a New Prognostic Factor and a Potential Therapeutic Target in ABC-DLBCL

A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): "Double Arm" CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

A Novel Cell Line, Tnet-2, Derived from "Triple-Negative" Essential Thrombocythemia

Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells

FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only